Can Adheriums AU$7.52 Million Equity Raising Accelerate Its Remote Patient Monitoring Growth?
Source: Kapitales Research
Highlights
Adherium Limited (ASX: ADR) is seeking to raise up to AU$7.52 million through a combination of an institutional placement and a pro-rata entitlement offer.
Funds will be used to advance commercialisation in the Remote Patient Monitoring (RPM) channel and support progress toward U.S. value-based care contracts.
The company is targeting more than 10,000 active RPM patients by the end of calendar year 2026.
Capital Raise to Support Commercial Expansion
Adherium Limited (ASX: ADR) has launched an equity raising to secure up to AU$7.52 million through the issue of approximately 2.51 billion new fully paid ordinary shares at a fixed offer price of AU$0.003 per share. The capital raising comprises an institutional placement expected to raise up to AU$1.34 million, alongside a 1-for-1.5 accelerated non-renounceable entitlement offer targeting up to AU$6.18 million.
The equity raising is not underwritten and is designed to strengthen the company’s balance sheet as it scales its respiratory monitoring platform across the United States.
Focus on Remote Patient Monitoring and Value-Based Care
Proceeds from the capital raising will be directed toward general working capital to support the expansion of Adherium’s Remote Patient Monitoring operations, staff recruitment, administrative costs, and repayment of creditors. The company is also positioning itself to progress toward value-based care contracts with U.S. insurers, leveraging data and infrastructure built through its RPM model.
According to the presentation, Adherium has established an operational platform servicing more than 2,100 RPM patients, with total shipments exceeding 4,600 devices. The company is targeting a significant increase in active RPM patients as it continues onboarding through clinic partners.
Growth Outlook and Market Opportunity
Adherium operates in a large and well-defined respiratory care market, with its serviceable addressable market in the United States estimated at approximately US$13 billion. Management expects continued momentum in RPM enrolments to underpin recurring revenue growth while preparing the business for higher-margin, outcomes-based value care agreements.
With enhanced reimbursement codes now in effect and multiple clinical partnerships in place, the company is working toward its stated goal of exceeding 10,000 active RPM patients by the end of 2026.
Disclaimer for Kapitales Research
The materials provided by Kapitales Research, including articles, news, data, reports, opinions, images, charts, and videos ("Content"), are intended for personal, non-commercial use only. The primary goal of this Content is to educate and inform readers. This Content is not meant to offer financial advice, nor does it include any recommendation or opinion that should be relied upon for making financial decisions. Certain Content on this platform may be sponsored or unsponsored, but it does not serve as a solicitation or endorsement to buy, sell, or hold any securities, nor does it encourage any specific investment activities. Kapitales Research is not authorized to provide investment advice, and we strongly advise users to seek guidance from a qualified financial professional, such as a financial advisor or stockbroker, before making any investment choices. Kapitales Research disclaims all liability for any direct, indirect, incidental, or consequential damages arising from the use of the Content, which is provided without any warranties. The opinions expressed by contributors or guests are their own and do not necessarily reflect the views of Kapitales Research. Media such as images or music used on this platform are either owned by Kapitales Research, sourced through paid subscriptions, or believed to be in the public domain. We have made reasonable efforts to credit sources where appropriate. Kapitales Research does not claim ownership of any third-party media unless explicitly stated otherwise.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au
x
Daily Dose of Buy, Sell & Hold recommendations before the market opens.
Start Your 7 Days Free Trial Now!
We use cookies to help us improve, promote, and protect our services.
By continuing to use this site, we assume you consent to this.
Read our
Privacy Policy
and
Terms & Conditions
Can Adheriums AU$7.52 Million Equity Raising Accelerate Its Remote Patient Monitoring Growth?
Highlights
Capital Raise to Support Commercial Expansion
Adherium Limited (ASX: ADR) has launched an equity raising to secure up to AU$7.52 million through the issue of approximately 2.51 billion new fully paid ordinary shares at a fixed offer price of AU$0.003 per share. The capital raising comprises an institutional placement expected to raise up to AU$1.34 million, alongside a 1-for-1.5 accelerated non-renounceable entitlement offer targeting up to AU$6.18 million.
The equity raising is not underwritten and is designed to strengthen the company’s balance sheet as it scales its respiratory monitoring platform across the United States.
Focus on Remote Patient Monitoring and Value-Based Care
Proceeds from the capital raising will be directed toward general working capital to support the expansion of Adherium’s Remote Patient Monitoring operations, staff recruitment, administrative costs, and repayment of creditors. The company is also positioning itself to progress toward value-based care contracts with U.S. insurers, leveraging data and infrastructure built through its RPM model.
According to the presentation, Adherium has established an operational platform servicing more than 2,100 RPM patients, with total shipments exceeding 4,600 devices. The company is targeting a significant increase in active RPM patients as it continues onboarding through clinic partners.
Growth Outlook and Market Opportunity
Adherium operates in a large and well-defined respiratory care market, with its serviceable addressable market in the United States estimated at approximately US$13 billion. Management expects continued momentum in RPM enrolments to underpin recurring revenue growth while preparing the business for higher-margin, outcomes-based value care agreements.
With enhanced reimbursement codes now in effect and multiple clinical partnerships in place, the company is working toward its stated goal of exceeding 10,000 active RPM patients by the end of 2026.
Disclaimer for Kapitales Research
The materials provided by Kapitales Research, including articles, news, data, reports, opinions, images, charts, and videos ("Content"), are intended for personal, non-commercial use only. The primary goal of this Content is to educate and inform readers. This Content is not meant to offer financial advice, nor does it include any recommendation or opinion that should be relied upon for making financial decisions. Certain Content on this platform may be sponsored or unsponsored, but it does not serve as a solicitation or endorsement to buy, sell, or hold any securities, nor does it encourage any specific investment activities. Kapitales Research is not authorized to provide investment advice, and we strongly advise users to seek guidance from a qualified financial professional, such as a financial advisor or stockbroker, before making any investment choices. Kapitales Research disclaims all liability for any direct, indirect, incidental, or consequential damages arising from the use of the Content, which is provided without any warranties. The opinions expressed by contributors or guests are their own and do not necessarily reflect the views of Kapitales Research. Media such as images or music used on this platform are either owned by Kapitales Research, sourced through paid subscriptions, or believed to be in the public domain. We have made reasonable efforts to credit sources where appropriate. Kapitales Research does not claim ownership of any third-party media unless explicitly stated otherwise.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au